Zobrazeno 1 - 10
of 272
pro vyhledávání: '"Eric Assenat"'
Autor:
Thibault Mazard, Caroline Mollevi, Evelyne M. Loyer, Julie Léger, Romain Chautard, Olivier Bouché, Christophe Borg, Paul Armand-Dujardin, Aurore Bleuzen, Eric Assenat, Thierry Lecomte
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background The Response Evaluation Criteria in Solid Tumors (RECIST) are often inadequate for the early assessment of the response to cancer therapy, particularly bevacizumab-based chemotherapy. In a first cohort of patients with colorectal
Externí odkaz:
https://doaj.org/article/d45f0dda6e3d4238af2a749c58b51981
Autor:
José Ursic-Bedoya, Guillaume Desandré, Carine Chavey, Pauline Marie, Arnaud Polizzi, Benjamin Rivière, Hervé Guillou, Eric Assenat, Urszula Hibner, Damien Gregoire
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 2, Pp 238-250 (2024)
Abstract FGF19 hormone has pleiotropic metabolic functions, including the modulation of insulin sensitivity, glucose/lipid metabolism and energy homeostasis. On top of its physiological metabolic role, FGF19 has been identified as a potentially targe
Externí odkaz:
https://doaj.org/article/68cb2332a4b943b799d98165f62d5be6
Autor:
Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L. Chan
Publikováno v:
JHEP Reports, Vol 6, Iss 4, Pp 101021- (2024)
Background & aims: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). Methods: Eligible patients who had progressed
Externí odkaz:
https://doaj.org/article/9e42ee62344d4ac28b99c8e6f48601dc
Autor:
Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, Dimitri Pureur, François Ghiringhelli, Eric Assenat, Pascal Hammel, Olivier Rosmorduc, Morgane Stouvenot, Manon Allaire, Mohamed Bouattour, Hélène Regnault, Serge Fratte, Eric Raymond, Emilie Soularue, Stéphanie Husson-Wetzel, Vincent Di Martino, Allison Muller, Anne-Laure Clairet, Christine Fagnoni-Legat, Olivier Adotevi, Aurélia Meurisse, Dewi Vernerey, Christophe Borg
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical activity in patients with hepatocellular carcinoma (HCC). However, the standard of care in first-line treatment with atezolizumab (anti-PD-L
Externí odkaz:
https://doaj.org/article/39a0fdecdfae4b14bb524649b02db940
Autor:
Emmanuel Deshayes, Eric Assenat, Laetitia Meignant, Manuel Bardiès, Lore Santoro, Sophie Gourgou
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Although neuroendocrine tumors (NET) are classed as rare, they have a high prevalence and their incidence is increasing. Effective treatment with lutetium 17-[177Lu]Lu-oxodotreotide (Lutathera®) is possible in patients with well-
Externí odkaz:
https://doaj.org/article/76f37742286647989418218941b0ad25
Autor:
Cecilia Gozzo, Margaux Hermida, Astrid Herrero, Fabrizio Panaro, Christophe Cassinotto, Azhar Meerun Mohamad, Eric Assenat, Chloé Guillot, Carole Allimant, Valentina Schembri, Antonio Basile, Sébastien Dharancy, José Ursic‐Bedoya, Boris Guiu
Publikováno v:
Hepatology Communications, Vol 6, Iss 10, Pp 2975-2987 (2022)
Abstract Percutaneous thermal ablation (PTA), resection, and liver transplantation are the standard curative options for hepatocellular carcinoma (HCC). Liver transplantation yields the best long‐term outcomes but is limited by graft shortage. Thus
Externí odkaz:
https://doaj.org/article/e83f01a2fff2422c9a14067e2b59f5f5
Autor:
Isabelle Serre, Olivier Lambotte, Stephane Ederhy, Jean-Marie Michot, Jean-Luc Faillie, Alexandre Thibault Jacques Maria, Xavier Quantin, Candice Lesage, Patricia Rullier, Philippe Guilpain, Romaric Larcher, Kada Klouche, Gerald Chanques, Mathieu Puyade, François Roubille, Nahéma Issa, Olivier Dereure, Cyrille Coustal, Juliette Vanoverschelde, Ariane Lappara, Eric Assenat, Maxime Faure, Diego Tosi, Hélène Vernhet-Kovacsik, Audrey Agullo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background Immune checkpoint inhibitors (ICI) have transformed cancer treatment over the last decade. Alongside this therapeutic improvement, a new variety of side effects has emerged, called immune-related adverse events (irAEs), potentially affecti
Externí odkaz:
https://doaj.org/article/d5144ff03e9341d0aea9a3c558f7092d
Autor:
Stephen L. Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean-Frederic Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Eric Assenat, Andrew X. Zhu, Thomas Yau, Ho Yeong Lim, Jordi Bruix, Andreas Geier, Carmen Guillén-Ponce, Angelica Fasolo, Richard S. Finn, Jia Fan, Arndt Vogel, Shukui Qin, Markus Riester, Vasiliki Katsanou, Monica Chaudhari, Tomoyuki Kakizume, Yi Gu, Diana Graus Porta, Andrea Myers, Jean-Pierre Delord
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-19 (2022)
Abstract Background Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclin
Externí odkaz:
https://doaj.org/article/1a80d93b46254b83bfdf5d4c0de1a368
Autor:
Zhenggang Ren, Michel Ducreux, Ghassan K. Abou-Alfa, Philippe Merle, Weijia Fang, Julien Edeline, Zhiwei Li, Lihua Wu, Eric Assenat, Sheng Hu, Lorenza Rimassa, Tao Zhang, Jean-Frédéric Blanc, Hongming Pan, Paul Ross, Chia-Jui Yen, Albert Tran, Guoliang Shao, Mohamed Bouattour, Yajin Chen, Tim Meyer, Jinlin Hou, David Tougeron, Yuxian Bai, Ming-Mo Hou, Zhiqiang Meng, John Wu, Vincent Li, Sandra Chica-Duque, Ann-Lii Cheng
Publikováno v:
Liver Cancer (2022)
Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficac
Externí odkaz:
https://doaj.org/article/5702df6d3dcb4d41bb1056d2e8bdf177
Autor:
Margaux Hermida, Ancelin Preel, Eric Assenat, Lauranne Piron, Christophe Cassinotto, José Ursic‐Bedoya, Chloé Guillot, Astrid Herrero, Fabrizio Panaro, Georges‐Philippe Pageaux, Boris Guiu
Publikováno v:
Hepatology Communications, Vol 5, Iss 4, Pp 689-700 (2021)
Percutaneous thermal ablation is a validated treatment option for small hepatocellular carcinoma (HCC). Steatotic HCC can be reliably detected by magnetic resonance imaging. To determine the clinical relevance of this radiological variant, we include
Externí odkaz:
https://doaj.org/article/bcd040aa28914c7ea7cf78c5a541772c